Executive Overview
Chimeric antigen receptor T-cell (CAR T) therapy stands as one of the most remarkable breakthroughs in modern oncology. By genetically re-engineering a patient’s own immune cells to selectively target and destroy malignant cells, this living drug has fundamentally transformed outcomes for individuals battling aggressive, treatment-resistant blood cancers such as relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). For patients facing rapid disease progression and otherwise consigned to palliative care, CAR T therapy offers a genuine, durable avenue toward remission and cure.
Yet, the extraordinary clinical promise of this cellular therapy is matched by an equally formidable array of logistical, financial, and structural barriers. Nowhere is this tension more apparent than in Brazil. Currently holding the distinction of being the sole country in Latin America with active access to commercial CAR T therapies, Brazil represents a micro-cosm of the broader global struggle to equitably deliver cutting-edge genomic medicine in resource-constrained environments.
With commercial manufacturing costs scaling up to USD 500,000 per patient—exclusive of profound ancillary expenses for complex hospitalization, specialized medical infrastructure, and the management of acute toxicities—widespread implementation remains heavily restricted. To address these compounding crises, the Americas Health Foundation convened a multidisciplinary panel of esteemed Brazilian experts in July 2025. Comprising leaders in hematology-oncology, regulatory science, public health administration, health technology assessment, and patient advocacy, the panel set out to dissect the underlying causes of healthcare disparity in Brazil and formulate a sustainable roadmap for equitable access. Their findings, published in Frontiers in Hematology, reveal a fragmented healthcare landscape plagued by delayed treatment timelines, stark divides between the public and private sectors, and a reliance on judicial litigation to secure life-saving care.
Detailed Chronology and Regulatory Evolution
The journey of CAR T therapy within Brazil’s borders is characterized by rapid regulatory milestones counterbalanced by institutional and operational inertia. Understanding this trajectory requires examining how scientific breakthroughs have intersected with national health policy over recent years:
- 2017–2021 (Global Proof and Early Regulatory Foundations): While the United States Food and Drug Administration (FDA) pioneered commercial cellular immunotherapy approvals starting with tisagenlecleucel in 2017, Brazilian regulatory bodies began establishing frameworks to review similar advanced therapy medicinal products (ATMPs). Clinical trials and initial regulatory pathways were laid down, though commercial availability remained virtually nonexistent for the general populace.
- 2022–2023 (Market Authorization Wave): Brazil’s National Health Surveillance Agency (ANVISA) granted marketing authorization for pioneering therapies. Axicabtagene ciloleucel (Yescarta) was approved in 2022 for adult patients with relapsed or refractory large B-cell lymphoma, followed by approvals for tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), and ciltacabtagene autoleucel (Carvykti) between 2022 and 2023. These approvals brought international standards of care to the country on paper, but left the immense operational and financial hurdles unresolved.
- July 2025 (The Americas Health Foundation Expert Convening): Recognizing that regulatory approval did not equal clinical access, a multidisciplinary panel met for a comprehensive, three-day summit. Driven by a pre-circulated evidence review using PubMed data and thematic working papers, the panel evaluated clinical efficacy, economic burdens, regulatory barriers, and infrastructure gaps. Their collaborative analysis laid the groundwork for a unified framework to address systemic bottlenecks.
- Current Day and Beyond: Brazil stands at a critical juncture. Between 2020 and 2024, a meager 104 patients managed to receive CAR T-cell therapy nationwide—a figure that starkly highlights the exclusion of thousands of eligible individuals who experience disease progression while trapped in administrative or legal limbo. Efforts are now shifting toward localized biomanufacturing collaborations, legislative modernization, and value-based reimbursement frameworks to bridge the widening equity gap.
Supporting Context and Metrics: The Ground Reality
To fully comprehend the gravity of the access crisis in Brazil, one must examine the clinical data, economic realities, and structural disparities that dictate patient outcomes.
Clinical Efficacy vs. Toxicity Realities
Clinical trials and real-world registries consistently demonstrate the profound durability of anti-CD19 CAR T therapies. For instance, pivotal studies like ELIANA for pediatric and young adult B-ALL demonstrated complete remission rates of 81%, with 12-month overall survival rates reaching 76%. Similarly, for diffuse large B-cell lymphoma (DLBCL), products like axi-cel and tisa-cel have yielded long-term overall survival rates hovering between 43% and 50%.
However, these remarkable responses come paired with significant therapeutic toxicities, most notably Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS). While clinical management algorithms for these conditions have matured, they require highly trained multidisciplinary teams, intensive care unit (ICU) readiness, and specialized infrastructure—capacities that are heavily concentrated in elite urban centers of excellence, leaving vast geographic regions underserved.
The Public-Private Divide and Judicialization
Brazil’s healthcare delivery is bifurcated into the publicly funded Unified Health System (Sistema Único de Saúde, SUS)—which serves approximately 75% of the population—and a private insurance market. Within the private sector, access has been severely hindered by the historic exclusion of CAR T therapies from the mandatory coverage list maintained by the National Regulatory Agency for Private Health Insurance and Plans (ANS).
When private insurers deny coverage under the defense that a therapy is "not on the list," patients are routinely forced into the judicial system. Empirical legal data reveals that Brazilian courts rule in favor of patients in an astonishing 96% of such disputes. While litigation acts as a vital safety valve for individual plaintiffs, it underscores a profound systemic failure: healthcare access should be a matter of routine clinical pathways rather than courtroom litigation.
+-------------------------------------------------------------------------+
| THE BRAZILIAN HEALTHCARE ACCESS DIVIDE |
+-----------------------------------+-------------------------------------+
| PUBLIC SECTOR (SUS) | PRIVATE INSURANCE |
+-----------------------------------+-------------------------------------+
| • Services 75% of population | • Fragmented reimbursement models |
| • Severe infrastructure deficits | • Historical exclusions from ANS |
| • Average timelines: 100-150 days | • Widespread reliance on litigation |
+-----------------------------------+-------------------------------------+The Domestic Manufacturing Imperative
Importing commercial CAR T products at costs approaching USD 500,000 is fiscally unsustainable for both SUS and private payers. Consequently, Brazil is making aggressive strides toward domestic biomanufacturing. A landmark partnership between Fundação Oswaldo Cruz (Fiocruz) and the U.S.-based non-profit Caring Cross aims to establish national production capabilities for leukemia and lymphoma therapies, targeting a revolutionary public health delivery cost of approximately USD 35,000 per dose.
Concurrently, collaborations between the Children’s Hospital of Philadelphia (CHOP) and the Brazilian National Cancer Institute (INCA)—backed by the Ministry of Health—are establishing automated manufacturing facilities for pediatric oncology. Research institutions like the University of São Paulo’s Center for Cell-Based Therapy (CTC) in Ribeirão Preto and the Butantan Institute are also advancing local clinical trials, marking a transformative shift toward national self-sufficiency and cost containment.
Official Perspectives and Expert Recommendations
The Americas Health Foundation expert panel synthesized their findings into actionable policy recommendations. Recognizing that piecemeal solutions will fail to address systemic dysfunction, the panel outlined a series of strategic interventions categorized by timeline and stakeholder responsibility:
- Iterative National Clinical Guidelines (Short-Term): Medical societies and public/private payers must collaborate to establish living clinical guidelines that explicitly define indication criteria, contraindications, toxicity management protocols, and long-term follow-up standards. Flexibility is paramount to adapt as domestic experience accumulates.
- Civil Society Task Forces (Short-Term): Forming dedicated task forces integrating government agencies, research bodies, and patient advocacy groups ensures that health technology policies remain anchored to patient needs and real-world realities.
- Continuous Multidisciplinary Training (Medium-Term): Hospitals and academic institutions must invest in rigorous technical training programs for physicians, specialized nurses, and clinical pharmacists to ensure safe administration and adverse event mitigation across an expanded network of treatment centers.
- National Patient Registry (Medium-Term): Spearheaded by the Ministry of Health and academic bodies, a centralized national database tracking all eligible and treated patients is essential for monitoring long-term efficacy, assessing 15-year safety profiles, and feeding real-world evidence into health technology assessments (HTAs).
- Streamlined Reimbursement and Public-Private Partnerships (Long-Term): Government bodies, ANVISA, and CMED must modernize pricing and reimbursement structures. Embracing outcome-based risk-sharing agreements—modeled after successful international frameworks—will ease financial toxicity. Simultaneously, scaling public-private partnerships will compress vein-to-vein times, bolster national security of supply, and democratize access across the oncology continuum.
Future Outlook and Global Context
As Brazil navigates this critical transition, it can draw valuable lessons from international counterparts. Countries like the United States, Germany, France, Spain, Japan, and the United Kingdom have deployed diverse strategies—ranging from temporary pre-approval access programs and managed access agreements to centralized hospital networks and longitudinal national registries.
For Brazil, the path forward requires moving beyond isolated pockets of excellence and establishing a unified, multisectoral national strategy. By coupling regulatory modernization with robust domestic manufacturing investments, value-based reimbursement models, and transparent lifecycle tracking, Brazil has the historic opportunity to transform CAR T therapy from an exclusive privilege for the few into an accessible pillar of universal healthcare.
The successful integration of cellular immunotherapy in Brazil will not only save thousands of domestic lives currently lost to administrative delays and disease progression; it will also serve as a pioneering, replicable framework for other resource-limited nations confronting the financial and logistical frontiers of 21st-century medicine.
